<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083522</url>
  </required_header>
  <id_info>
    <org_study_id>ISEE_2017_OJS</org_study_id>
    <nct_id>NCT03083522</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet</brief_title>
  <acronym>OJS</acronym>
  <official_title>Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet - A Randomized, Double-blinded, Placebo Controlled, Multi-center Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chan-Yong Jeon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kyunghee University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyung Hee University Hospital at Gangdong</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Semyung University Affiliated Oriental Medical Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gachon University Gil Oriental Medical Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this trial is to investigate the efficacy and safety of Ojeok-san(OJS) on&#xD;
      Korean Patients With Cold Hypersensitivity in the Hands&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Actual">November 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 14, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline in visual analogue scale</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in body temperature</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in WHOQoL-BREF</measure>
    <time_frame>At baseline, week 4, 8, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in cold stress test</measure>
    <time_frame>At baseline, week 8</time_frame>
    <description>similar to the cold stimulation test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Sign</measure>
    <time_frame>every visit</time_frame>
    <description>Body temperature, blood pressure, pulse rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>At screening visit, week 8</time_frame>
    <description>Levels of AST, ALT and r-GTP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function test</measure>
    <time_frame>At screening visit, week 8</time_frame>
    <description>Levels of BUN and Cr</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood count</measure>
    <time_frame>At screening visit, week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>At week 4, 8, 12</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pattern Identification Questionnaire</measure>
    <time_frame>At screening visit</time_frame>
    <description>This questionnaire is a traditional medicine researcher self-developed questionnaire for collecting general symptoms of patients with Cold Hypersensitivity in the Hands and feet</description>
  </other_outcome>
  <other_outcome>
    <measure>Cold Hypersensitivity diagnostic tool</measure>
    <time_frame>At screening visit</time_frame>
    <description>This tool is a traditional medicine researcher self-developed questionnaire of screening for patients with Cold Hypersensitivity in the Hands and feet In this trial, we will assess the validity of the tool.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cold Hypersensitivity</condition>
  <arm_group>
    <arm_group_label>OJS group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>admission to Ojeok-san granule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>admission to placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ojeok-San</intervention_name>
    <description>Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
    <arm_group_label>OJS group</arm_group_label>
    <other_name>OJS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM &amp; FOODS Co. Ltd.</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>corn starch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female subjects aged 19 to 59 years have a complaint of CHH.&#xD;
&#xD;
          2. Patients must include at least one or more of the following symptoms:&#xD;
&#xD;
               -  Those who have the symptoms of CHH in normal temperature which most individuals&#xD;
                  feel no cold;&#xD;
&#xD;
               -  Those who have the symptoms of extremely cold hands in cold temperature exposure;&#xD;
&#xD;
               -  Those who are on the return to a warmer environment, the symptoms of cold hands&#xD;
                  is not completely rewarmed;&#xD;
&#xD;
          3. Those who have 4 cm or greater of VAS CHH score;&#xD;
&#xD;
          4. A thermal differences between the palm (PC8) and the upper arm (LU4) may be higher&#xD;
             than 0.3â„ƒ;&#xD;
&#xD;
          5. Those who can comply with all study-related procedures, medications, and evaluations;&#xD;
&#xD;
          6. Given a written informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with calcium antagonists or beta-blockers with the purpose of treating CHH;&#xD;
&#xD;
          2. Those who have one or more finger gangrene or ulceration;&#xD;
&#xD;
          3. Those who are diagnosed by hypothyroidism or currently medicated to thyroid drugs;&#xD;
&#xD;
          4. Those who are diagnosed by autoimmune disease or have a positive ANA test result;&#xD;
&#xD;
          5. Those who are diagnosed by carpal tunnel syndrome or have a positive Tinel and&#xD;
             Phalen's tests;&#xD;
&#xD;
          6. Those who are diagnosed with cervical disc herniation or (malignant) tumor disease;&#xD;
&#xD;
          7. Those who are diagnosed with diabetes;&#xD;
&#xD;
          8. Those who are currently medicated to drugs that may affect to CHH symptoms, such as&#xD;
             anticoagulants etc;&#xD;
&#xD;
          9. Those who have moderate level of liver dysfunction (each of AST, ALT greater than 100&#xD;
             IU/L) or kidney dysfunction (Cr 2.0mg/dL);&#xD;
&#xD;
         10. Those who do not (cannot) abide by treatment and follow up due to the mental illness&#xD;
             such as behavior disorder, depression, anxiety neurosis, schizophrenia, or serious&#xD;
             mental illness;&#xD;
&#xD;
         11. Those who are Diagnosed with moderate anemia and hematologic disorders (adult&#xD;
             non-pregnant women hemoglobin (Hgb) level less than 7g/dL, hematocrit (Hct) level less&#xD;
             than 26%, white blood cell (WBC) level greater than 11,000/mm3);&#xD;
&#xD;
         12. Those whose systolic blood pressure (SBP) 180mmHg or diastolic blood pressure (DBP) is&#xD;
             greater than 100 mmHg based on average value of at least 2 measurements;&#xD;
&#xD;
         13. Those who are suspected arrhythmia that showing up on ECG, or diagnosed by heart&#xD;
             diseases, such as, ischemic heart disease and so on;&#xD;
&#xD;
         14. Those who are addicted to alcohol or drugs;&#xD;
&#xD;
         15. Those who are pregnant (positive urine-HCG) or lactating or have the chances of&#xD;
             pregnancy;&#xD;
&#xD;
         16. Those who are diagnosed with malignant tumor&#xD;
&#xD;
         17. Those who are currently participated in other clinical trials;&#xD;
&#xD;
         18. Those who are unable to understand and speak Korean;&#xD;
&#xD;
         19. Those who are judged to be inappropriate for the clinical study by the researchers.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chanyong Jeon, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Gachon University Gil Oriental Medical Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyung Hee university medical center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <last_update_submitted>December 28, 2019</last_update_submitted>
  <last_update_submitted_qc>December 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Gachon University Gil Oriental Medical Hospital</investigator_affiliation>
    <investigator_full_name>Chan-Yong Jeon</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Cold Hypersensitivity</keyword>
  <keyword>Korean medicine</keyword>
  <keyword>Ojeok-san</keyword>
  <keyword>Cold intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

